Aquestive's second quarter landed on the same day as one of the more consequential capital-structure events in the company's history, and the print itself was a study in dualities. Total revenue rose 38% year over year to $13.8 million, with the manufacture-and-supply line and a freshly-larger license/royalty line doing all the work. The GAAP net loss widened to $22.9 million, or $0.18 per share, almost entirely because of an $11.7 million one-time loss on extinguishment of debt tied to the May 12, 2026 refinancing of the legacy 13.5% Senior Secured Notes with a new $55 million Oaktree Term Loan A. Strip that out, as management does, and the quarter's net loss was $11.2 million. Non-GAAP adjusted EBITDA loss was $5.2 million versus $9.3 million a year ago, a 44% improvement that says the operating engine is tightening even as the top line rebuilds. The whole quarter really sits in three movements: the new $55 million Oaktree loan replaced the 13.5% Notes (and came with $95 million in unfunded additional tranches), Anaphylm's NDA resubmission is reaffirmed for the third quarter, and operating burn is now running 22% lower year over year. Each is a story. Together they make the quarter a different kind of readout than the headline GAAP loss implies.
The story of the next twelve months is the NDA. Management reaffirmed the third-quarter 2026 resubmission of Anaphylm and completed both the human factors validation study and the pharmacokinetic study the FDA asked for in its January 30, 2026 Complete Response Letter, with management saying the human-factors work "showed significant improvement across each deficiency" and the PK study met its primary endpoints. The CRL did not cite any CMC or clinical-comparability issues, so the resubmission is a packaging-and-labeling fix, not a fresh clinical trial. The cash position at quarter-end of $98.5 million, paired with the new Oaktree term loan, the $73 million remaining on the ATM, and an annualized H1 2026 operating burn of roughly $49 million, funds a runway through the expected PDUFA and into the early launch period. The capital structure looks settled for the first time in years.
The valuation, on the other hand, is doing what the valuation does for a single-asset biotech at this stage: pricing the option. At a reference price of $4.24 on August 13, 2026, Aquestive trades at a $531 million market cap and an enterprise value of roughly $574 million once the term loan, the residual 13.5%-era royalty obligations, the Oaktree-related sale-of-future-revenue liability, and the cash position are all in the math. EV/Sales sits near 10x trailing and 10x on a Q2 annualized basis, price-to-cash near 5.4x, and stockholders' equity is negative at $(56.6) million - a number that is structural rather than informational for a single-asset clinical-stage company with accumulated losses of $477.9 million. The market is paying for the optionality on Anaphylm approval, not for the GAAP balance sheet, and the same is true for the Anaphylm-launch ramp that follows. A CRL-driven delay to 2027 or an approval with a slow allergist-office ramp would compress the multiple sharply; a clean approval with a fast office ramp would expand it.